Genenta Science Shares Are Trading Higher After the Company Announced the Agenzia Italiania Del Farmaco Approved Its Phase 1 Trial for Metastatic Renal Cell Cancer for Its Flagship Product. Additionally, HC Wainwright & Co Reiterated a Buy Rating on...

Benzinga · Oct 3 01:07

Genenta Science Shares Are Trading Higher After the Company Announced the Agenzia Italiania Del Farmaco Approved Its Phase 1 Trial for Metastatic Renal Cell Cancer for Its Flagship Product. Additionally, HC Wainwright & Co Reiterated a Buy Rating on the Stock and Maintained Its $25 Price Target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Genenta Science Shares Are Trading Higher After the Company Announced the Agenzia Italiania Del Farmaco Approved Its Phase 1 Trial for Metastatic Renal Cell Cancer for Its Flagship Product. Additionally, HC Wainwright & Co Reiterated a Buy Rating on...

Genenta Science Shares Are Trading Higher After the Company Announced the Agenzia Italiania Del Farmaco Approved Its Phase 1 Trial for Metastatic Renal Cell Cancer for Its Flagship Product. Additionally, HC Wainwright & Co Reiterated a Buy Rating on the Stock and Maintained Its $25 Price Target.

Risk Disclaimer